CEO Today USA Awards

NEW JERSEY www.ceotodaymagazine.com 80 CEO Today USAAwards 2017 Agile Therapeutics is a forward- thinking women’s healthcare company dedicated to fulfilling the unmet health needs of to- day’s women. Our product can- didates are designed to provide women with contraceptive op- tions that offer freedom from taking a daily pill, without com- mitting to a longer-acting meth- od. Our lead product candi- date, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200- 15, is a once-weekly prescrip- tion contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is in- tended to optimize patch adhe- sion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. FIRM PROFILE ABOUT AL ALTOMARI After a distinguished career in the global pharmaceutical industry, and more than twenty years focused on the development and marketing of specialty pharmaceuticals, Al Altomari currently serves as Agile Therapeutics’ Chairman and Chief Executive Officer. Having blazed his own trail in the pharmaceutical industry, launching a successful career with companies that developed and commercialized innovative women’s healthcare and dermatology products, Mr. Altomari is now leading the company through the final stages of the development of a novel contraceptive patch using the company’s proprietary transdermal technology. Having previously served as Chairman of the Company’s Board of Directors from 2004 to 2010, Mr. Altomari took over the helm of the company in 2010 and assembled a new management team bringing a unique experience to the women’s health field. Having rallied its capital and resources around developing a novel product in the almost-abandoned field of women’s health related to contraception, he organized a confirmatory Phase 3 trial of the company’s novel contraceptive patch. Leading the way, Mr. Altomari’s focus has been on the execution of the company’s core strategic objectives to address an unmet need of providing women with new contraception options. Over the past several years, he has been instrumental in securing the necessary funding to sustain business operations which included taking the company public in 2014. In doing so, he has raised over $100 million of much-needed capital that was invested in the company’s clinical development program and commercial preparations for its novel contraceptive patch, with the goal to bring its first product to market. Through his proven leadership and passion to develop better treatment options, he has led the transformation of the dynamic and pioneering spirit found in the company today. Before joining Agile Therapeutics, Mr. Altomari served as Chief Executive Officer of Barrier Therapeutics and in 2008, completed the successful sale of the company to Stiefel Laboratories at a 73% premium, which subsequently GlaxoSmithKline plc acquired. Preceding Barrier Therapeutics, he spent over twenty years within Johnson & Johnson including serving as Vice President, Franchise Head of Ortho-McNeil Pharmaceuticals Women’s Health Care for which global product sales were in excess of $1 billion. During his tenure there, Mr. Altomari led the introduction of several life- cycle and new product development initiatives and successfully planned the launch of other products including a first-in-class contraceptive patch. Having headed the division that brought the first transdermal contraceptive patch to market, he is now looking to bring the first low-dose transdermal contraceptive to the market, if approved. Over the past several years, he has been acknowledged for his outstanding contributions including being recognized as one of the Top 100 Most Inspirational and Influential Leaders in the Life Sciences Industry by PharmaVoice Magazine in both 2007 and 2017. In 2016, he was recognized as CEO of the Year by Finance Monthly Magazine and in 2014, he was recognized as CEO of the Year by the New Jersey Technology Council. During 2017, Mr. Altomari was inducted into the Father Judge High School Hall of Fame for his longtime support and contributions to achieving academic excellence and providing educational opportunities to deserving children. In 2016, he was awarded “Father of the Year” from the American Diabetes Association. Mr. Altomari currently serves as a member of the Board of Directors of Insmed Inc., and Recro Pharma, Inc. He received a Master of Business Administration degree from Rider University and a Bachelor of Science degree from Drexel University with a dual major in finance and accounting. In 2017, Mr. Altomari was inducted into the prestigious Drexel 100 Hall of Fame in recognition of his lifetime achievements. He currently serves on the LeBow College of Business Advisory Board and the Advisory Board of the Charles D. Close School of Entrepreneurship at Drexel University and Vice Chairman of the Board for the Trenton Area Soup Kitchen (TASK). AL ALTOMARI Chairman and Chief Executive Officer of Agile Therapeutics www.agiletherapeutics.com